SZU-106

**SZU-106** is a synthetic small molecule **Toll-like receptor 7 (TLR7) agonist** developed for immunotherapy applications, notably in cancer. SZU-106 selectively activates TLR7 and increases the expression of SEAP by activating the NF-κB pathway. It induces secretion of key pro-inflammatory cytokines, including interferon gamma (IFN-γ) and interleukin 6 (IL-6), and promotes dendritic cell maturation and T cell activation[1][3][5]. SZU-106 is suitable for conjugation to tumor cells and has been studied as a component of whole-tumor-cell vaccines for enhancing antitumor immune responses in preclinical models of melanoma and acute myeloid leukemia. It is not approved for human use and is currently used as a research tool.